Literature DB >> 29071443

Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis.

Erol Senturk1, Yavuz Selim Yildirim2, Remzi Dogan2, Orhan Ozturan2, Eray Metin Guler3, Mehmet Serif Aydin4, Abdurrahim Kocyigit3, Mukaddes Esrefoglu4, Ilker Kocak5.   

Abstract

The aim of this study is to show if cyclosporine has an antiallergic role in a rat model of ovalbumin-induced allergic rhinitis. The 54 rats were divided into six equal groups. The first group was a negative control group without induced allergic rhinitis; the second group a positive control with induced allergic rhinitis not receiving treatment. The remaining four groups, after induction of allergic rhinitis, received intranasal cyclosporine treatment in doses of 0.05, 0.1, or 0.2% or nasal steroid treatment. In the biochemical examination, on the surface of the tissue tumor necrosis factor (TNF) interferon (IFN), interleukin (IL)-5, IL-13, as well as IL-2, IL-4, IL-17A, and IgE were studied. Histologically, ciliary loss, increase of goblet cells, vascular congestion, and the degree of eosinophil infiltration were rated. In all treatment groups, on average, a significant reduction in all histological and biochemical values was found compared to the positive control group. Comparing each of the three cyclosporine-using groups with the group of nasal corticosteroid did not show any significant difference in the average scores. Cyclosporine nasal drops are effective to be used in an animal model of experimental allergic rhinitis without systemic effects.

Entities:  

Keywords:  Allergic rhinitis; Corticosteroid; Cyclosporine; Immunosuppressive; Nasal spray; Rat

Mesh:

Substances:

Year:  2017        PMID: 29071443     DOI: 10.1007/s00405-017-4786-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  32 in total

Review 1.  The use of cyclosporine in dermatology: part I.

Authors:  Karrie T Amor; Caitriona Ryan; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2010-12       Impact factor: 11.527

Review 2.  Mechanisms of action of cyclosporine.

Authors:  S Matsuda; S Koyasu
Journal:  Immunopharmacology       Date:  2000-05

3.  Effects of topical application of methotrexate on nasal mucosa in rats: a preclinical assessment study.

Authors:  Ibrahim Ercan; Burak Omür Cakir; Tülay Başak; Eltaf Ayça Ozbal; Atilla Sahin; Gürhan Balci; Suat Turgut
Journal:  Otolaryngol Head Neck Surg       Date:  2006-05       Impact factor: 3.497

4.  Correlation of immunoglobulin E, eosinophil cationic protein, and eosinophil count with the severity of childhood perennial allergic rhinitis.

Authors:  Shuei Tu Chen; Hai Lun Sun; Ko Hsiu Lu; Ko Huang Lue; Ming Chih Chou
Journal:  J Microbiol Immunol Infect       Date:  2006-06       Impact factor: 4.399

Review 5.  Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators.

Authors:  R S Zeiger; M Schatz
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

6.  Therapeutic effects of intranasal cyclosporine for eosinophilic rhinosinusitis with nasal polyps in a mouse model.

Authors:  Dong-Yeop Chang; Yeon-Hee Joo; Seong-Jae Kim; Jin Hyun Kim; Myeong Hee Jung; Dae Woo Kim; Sea-Yuong Jeon; Sang-Wook Kim
Journal:  Am J Rhinol Allergy       Date:  2015 Jan-Feb       Impact factor: 2.467

7.  Th1- and Th2-type cytokines in chronic ocular allergy.

Authors:  Andrea Leonardi; Iva A Fregona; Mario Plebani; Antonio G Secchi; Virginia L Calder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

Review 8.  Topical ophthalmic cyclosporine: pharmacology and clinical uses.

Authors:  Eric Donnenfeld; Stephen C Pflugfelder
Journal:  Surv Ophthalmol       Date:  2009 May-Jun       Impact factor: 6.048

9.  Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma.

Authors:  Raffi Tachdjian; Clinton Mathias; Shadi Al Khatib; Paul J Bryce; Hong S Kim; Frank Blaeser; Brian D O'Connor; Danuta Rzymkiewicz; Andrew Chen; Michael J Holtzman; Gurjit K Hershey; Holger Garn; Hani Harb; Harald Renz; Hans C Oettgen; Talal A Chatila
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

10.  Anti-Interleukin-1 Beta/Tumor Necrosis Factor-Alpha IgY Antibodies Reduce Pathological Allergic Responses in Guinea Pigs with Allergic Rhinitis.

Authors:  Hu Wei-Xu; Zhou Wen-Yun; Zhu Xi-Ling; Wen Zhu; Wu Li-Hua; Wu Xiao-Mu; Wei Hui-Ping; Wang Wen-Ding; He Dan; Xiang Qin; Hu Guo-Zhu
Journal:  Mediators Inflamm       Date:  2016-03-07       Impact factor: 4.711

View more
  4 in total

1.  The ameliorative effect of berberine and coenzyme Q10 in an ovalbumin-induced allergic rhinitis model.

Authors:  Muhammed Sedat Sakat; Korhan Kilic; Fatih Mehmet Kandemir; Serkan Yildirim; Abdulkadir Sahin; Sefa Kucukler; Yavuz Selim Saglam
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-23       Impact factor: 2.503

2.  The amendatory effect of hesperidin and thymol in allergic rhinitis: an ovalbumin-induced rat model.

Authors:  Korhan Kilic; Muhammed Sedat Sakat; Serkan Yildirim; Fatih Mehmet Kandemir; Mustafa Sitki Gozeler; Muhammed Bahaeddin Dortbudak; Sefa Kucukler
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-11-28       Impact factor: 2.503

3.  A novel nasal co-loaded loratadine and sulpiride nanoemulsion with improved downregulation of TNF-α, TGF-β and IL-1 in rabbit models of ovalbumin-induced allergic rhinitis.

Authors:  Soad A Mohamad; Mohamed A Safwat; Mahmoud Elrehany; Sherif A Maher; Ahmed M Badawi; Heba F Mansour
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  Effect of parasympathetic inhibition on expression of ILC2 cells in a mouse model of allergic rhinitis.

Authors:  Binbin Hu; Yan Wang; Guotong Zheng; Hailin Zhang; Liyan Ni
Journal:  World Allergy Organ J       Date:  2021-10-01       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.